GAIN THERAPEUTICS, INC (GANX) Current Ratio
- Current ratio · latest quarter: Value 4.36×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 4.36× | Current assets / current liabilities. $14.97M ÷ $3.43M ≈ 4.36× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 14.97M USD | Assets, Current |
| Current obligations | 3.43M USD | Liabilities, Current |
| Cash and equivalents | 13.08M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | Marketable Securities, Current |
| Customer receivables | (m) | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory | (m) | |
| Payables | 1.22M USD | Accounts Payable, Current |
| Borrowing debt due within one year | 123.63K USD | Long-term Debt, Current Maturities |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $14.97M | $3.43M | $13.08M | (m) | (m) | (m) | $1.22M | $123.63K | 4.36× |
| 2026-03-31 | $18.22M | $3.89M | $16.54M | (m) | (m) | (m) | $1.52M | $100.28K | 4.69× |
| 2025-12-31 | $22.24M | $3.35M | $20.84M | (m) | (m) | (m) | $825.03K | $100.87K | 6.63× |
| 2025-09-30 | $10.52M | $4.17M | $8.81M | (m) | (m) | (m) | $1.58M | $125.55K | 2.52× |
| 2025-06-30 | $9.31M | $5.20M | $6.69M | (m) | (m) | (m) | $2.71M | $126.11K | 1.79× |
| 2025-03-31 | $11.15M | $5.03M | $9.07M | (m) | (m) | (m) | $2.15M | $113.12K | 2.22× |
| 2024-12-31 | $11.60M | $3.91M | $10.39M | (m) | (m) | (m) | $946.26K | $110.18K | 2.97× |
| 2024-09-30 | $13.74M | $4.59M | $12.05M | (m) | (m) | (m) | $1.10M | $118.28K | 2.99× |
| 2024-06-30 | $18.54M | $6.52M | $16.94M | (m) | (m) | (m) | $2.05M | $111.05K | 2.84× |
| 2024-03-31 | $13.86M | $5.00M | $10.64M | $2.02M | (m) | (m) | $1.41M | $110.85K | 2.77× |
| 2023-12-31 | $17.78M | $4.95M | $11.79M | $5.00M | (m) | (m) | $1.32M | $118.80K | 3.59× |
| 2023-09-30 | $13.24M | $5.76M | $4.27M | $7.96M | (m) | (m) | $1.38M | $109.28K | 2.30× |
| 2023-06-30 | $17.31M | $5.59M | $6.32M | $9.87M | (m) | (m) | $924.39K | $111.64K | 3.10× |
| 2023-03-31 | $19.32M | $5.15M | $5.99M | $11.83M | (m) | (m) | $2.21M | $109.20K | 3.75× |
| 2022-12-31 | $21.09M | $4.13M | $7.31M | $12.83M | (m) | (m) | $1.63M | $108.14K | 5.11× |
| 2022-09-30 | $24.35M | $4.33M | $10.88M | $11.85M | (m) | (m) | $1.02M | $101.26K | 5.62× |
| 2022-06-30 | $25.83M | $3.41M | $14.31M | $9.94M | (m) | (m) | $948.90K | $83.75K | 7.58× |
| 2022-03-31 | $36.39M | $4.22M | $34.34M | (m) | (m) | (m) | $2.12M | $86.62K | 8.63× |
| 2021-12-31 | $37.72M | $2.55M | $36.88M | (m) | (m) | (m) | $560.48K | $103.83K | 14.78× |
| 2021-09-30 | $41.55M | $3.58M | $40.98M | (m) | $24.71K | (m) | $789.39K | $86.64K | 11.62× |
| 2021-06-30 | $44.34M | $2.45M | $43.16M | (m) | $353.17K | (m) | $978.39K | $65.47K | 18.09× |
| 2021-03-31 | $47.38M | $2.33M | $46.59M | (m) | $4.49K | (m) | $881.75K | $44.29K | 20.37× |
| 2020-12-31 | $8.99M | $2.11M | $7.49M | (m) | $8.55K | (m) | $961.52K | $22.63K | 4.25× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B |